Logo image of MDGL

MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Fundamental Analysis

NASDAQ:MDGL - Nasdaq - US5588681057 - Common Stock - Currency: USD

336.23  -14.8 (-4.22%)

After market: 336.23 0 (0%)

Fundamental Rating

2

MDGL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. The financial health of MDGL is average, but there are quite some concerns on its profitability. MDGL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MDGL has reported negative net income.
MDGL had a negative operating cash flow in the past year.
In the past 5 years MDGL always reported negative net income.
In the past 5 years MDGL always reported negative operating cash flow.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

MDGL's Return On Assets of -47.92% is in line compared to the rest of the industry. MDGL outperforms 48.31% of its industry peers.
MDGL has a Return On Equity of -60.97%. This is comparable to the rest of the industry: MDGL outperforms 59.86% of its industry peers.
Industry RankSector Rank
ROA -47.92%
ROE -60.97%
ROIC N/A
ROA(3y)-76.09%
ROA(5y)-63.54%
ROE(3y)-121.71%
ROE(5y)-93.9%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MDGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, MDGL has more shares outstanding
Compared to 5 years ago, MDGL has more shares outstanding
MDGL has a worse debt/assets ratio than last year.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 16.55 indicates that MDGL is not in any danger for bankruptcy at the moment.
MDGL has a Altman-Z score of 16.55. This is amongst the best in the industry. MDGL outperforms 91.47% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that MDGL is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.14, MDGL is doing worse than 68.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 16.55
ROIC/WACCN/A
WACCN/A
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 9.39 indicates that MDGL has no problem at all paying its short term obligations.
MDGL has a Current ratio of 9.39. This is in the better half of the industry: MDGL outperforms 78.51% of its industry peers.
A Quick Ratio of 9.39 indicates that MDGL has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.39, MDGL is doing good in the industry, outperforming 78.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.39
Quick Ratio 9.39
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

MDGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.35%.
EPS 1Y (TTM)-30.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MDGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.41% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-20.07%
EPS Next 2Y14.35%
EPS Next 3Y29.31%
EPS Next 5Y37.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 50 100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MDGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MDGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20

4.3 Compensation for Growth

MDGL's earnings are expected to grow with 29.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.35%
EPS Next 3Y29.31%

More info and screens

0

5. Dividend

5.1 Amount

MDGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (2/21/2025, 8:00:01 PM)

After market: 336.23 0 (0%)

336.23

-14.8 (-4.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)02-26 2025-02-26/bmo
Inst Owners96.65%
Inst Owner Change-96.03%
Ins Owners5.45%
Ins Owner Change-2.17%
Market Cap7.33B
Analysts81.82
Price Target388.42 (15.52%)
Short Float %20%
Short Ratio10.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.86%
Min EPS beat(2)7.5%
Max EPS beat(2)30.22%
EPS beat(4)2
Avg EPS beat(4)4.3%
Min EPS beat(4)-15.12%
Max EPS beat(4)30.22%
EPS beat(8)3
Avg EPS beat(8)2.42%
EPS beat(12)5
Avg EPS beat(12)0.91%
EPS beat(16)8
Avg EPS beat(16)2%
Revenue beat(2)2
Avg Revenue beat(2)172.99%
Min Revenue beat(2)78.29%
Max Revenue beat(2)267.7%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.09%
PT rev (3m)5.04%
EPS NQ rev (1m)1.74%
EPS NQ rev (3m)0.32%
EPS NY rev (1m)0.75%
EPS NY rev (3m)0.69%
Revenue NQ rev (1m)6.79%
Revenue NQ rev (3m)4.93%
Revenue NY rev (1m)1.44%
Revenue NY rev (3m)2.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 95.47
P/FCF N/A
P/OCF N/A
P/B 8.62
P/tB 8.67
EV/EBITDA N/A
EPS(TTM)-25.08
EYN/A
EPS(NY)-13.81
Fwd EYN/A
FCF(TTM)-20.1
FCFYN/A
OCF(TTM)-19.76
OCFYN/A
SpS3.52
BVpS39.01
TBVpS38.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.92%
ROE -60.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.09%
ROA(5y)-63.54%
ROE(3y)-121.71%
ROE(5y)-93.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 839.77%
Cap/Sales 9.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.39
Quick Ratio 9.39
Altman-Z 16.55
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)126.22%
Cap/Depr(5y)120.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.87%
EPS Next Y-20.07%
EPS Next 2Y14.35%
EPS Next 3Y29.31%
EPS Next 5Y37.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-57.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.69%
EBIT Next 3Y22.52%
EBIT Next 5YN/A
FCF growth 1Y-104.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.04%
OCF growth 3YN/A
OCF growth 5YN/A